
BYL-719
CAS No. 1217486-61-7
BYL-719 ( Alpelisib )
产品货号. M10815 CAS No. 1217486-61-7
Alpelisib (BYL-719) 是一种有效的选择性 PI3Kα 抑制剂,在无细胞测定中 IC50 为 5 nM,对 PI3Kβ/γ/δ 的影响极小。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥405 | 有现货 |
![]() ![]() |
10MG | ¥535 | 有现货 |
![]() ![]() |
25MG | ¥640 | 有现货 |
![]() ![]() |
50MG | ¥786 | 有现货 |
![]() ![]() |
100MG | ¥1264 | 有现货 |
![]() ![]() |
200MG | ¥2260 | 有现货 |
![]() ![]() |
500MG | ¥3815 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称BYL-719
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Alpelisib (BYL-719) 是一种有效的选择性 PI3Kα 抑制剂,在无细胞测定中 IC50 为 5 nM,对 PI3Kβ/γ/δ 的影响极小。
-
产品描述Alpelisib (BYL-719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.(In Vitro):Alpelisib (BYL-719) potently inhibits the 2 most common PIK3CA somatic mutations (H1047R, E545K; IC50s~4 nM). Alpelisib potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74±15 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (≥15-fold compared with PI3Kα).Alpelisib (BYL-719, 0-50 μM; 72 hours) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner.Alpelisib (BYL-719) significantly alters the distribution of cell cycle phases. Alpelisib (BYL-719, 25 μM; 18 hours) induces a cell cycle arrest in the G0/G1 phase of human and murine osteosarcoma cell lines.(In Vivo):Alpelisib (BYL-719) (12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice; oral administration; daily) significantly reduces tumor volumes and deposition of ectopic bone matrix.Alpelisib has moderate terminal elimination half-life (t1/2=2.9±0.2 h) for rat (1 mg/kg, iv) .
-
体外实验——
-
体内实验Animal Model:A 5-week-old female Rj:NMRI-nude mice withhuman HOS-MNNG osteosarcoma cells; A 5-week-old male C57Bl/6J mice with mouse MOS-J osteosarcoma cells Dosage:12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice Administration:Oral administration; daily; 22 or 29 days for C57Bl/6J mice or Rj:NMRI-nude mice Result:Significantly reduced tumor volumes and simultaneously reduced tumor growth.Animal Model:Female Sprague Dawley rats Dosage:1 mg/kg (Pharmacokinetic Analysis)Administration:I.V.Result:t1/2=2.9±0.2 hours.
-
同义词Alpelisib
-
通路PI3K/Akt/mTOR signaling
-
靶点PI3K
-
受体PI3Kα
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1217486-61-7
-
分子量441.47
-
分子式C19H22F3N5O2S
-
纯度>98% (HPLC)
-
溶解度Ethanol: 2 mg/mL (4.53 mM); DMSO: 88 mg/mL (199.33 mM)
-
SMILESO=C(N1[C@H](C(N)=O)CCC1)NC2=NC(C)=C(C3=CC(C(C)(C)C(F)(F)F)=NC=C3)S2
-
化学全称(S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Dejan Juric, et al. 2012, AACR 103rd Annual Meeting. Abst CT-0
产品手册




关联产品
-
Trihexyphenidyl hydr...
Trihexyphenidyl Hydrochloride 是一种抗毒蕈碱类抗帕金森病药。
-
IHMT-PI3Kδ-372 S-iso...
IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56~83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.
-
AZD 6482
一种有效的、选择性的 ATP 竞争性 PI3Kβ 抑制剂,IC50 为 10 nM。